Amelioration of experimental autoimmune encephalomyelitis by BLyS autovaccine

SummaryThe B-lymphocyte stimulator (BLyS) is implicated in various pathophysiological processes. The overexpression of BLyS has been observed in some human diseases, including systemic lupus erythematosus, rheumatoid arthritis, Sjögren's syndrome, and multiple sclerosis. This feature suggests that BLyS may be a therapeutic target for some human autoimmune diseases. We developed a therapeutic vaccine by coupling a tetanus toxoid T-helper cell epitope with the C-terminal of BLyS (TT-BLyS). This vaccine can induce high titers of neutralizing antibodies against BLyS in an animal model; the antibody has markedly protective effects on experimental autoimmune encephalomyelitis in rats, which is induced by inoculation of spinal cord homogenate. Our data suggest that the BLyS autovaccine may be a useful candidate for the treatment of some autoimmune diseases associated with the production of BLyS.